Accessibility StatementSkip Navigation SOUTH SAN FRANCISCO, Calif., Nov. 24, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events. Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Yigal D. Nochomovitz, Ph.D., Director, SMid Cap Biotech Analyst 8th Annual Evercore Healthcare ConferenceWedn ...

Core Insights - Caris Life Sciences has selected 15 physician-scientists for its 2025/2026 Caris Precision Oncology Alliance (Caris POA) Fellows Forum, aimed at enhancing early-career oncologists' skills in precision medicine [1][2][4] Group 1: Program Overview - The Caris POA Fellows Forum is a competitive two-year program providing mentorship, training, and access to real-world molecular data for early-career oncologists [1][2] - Selected fellows will engage in data analysis, seminars, and mentorship sessions to deepen their expertise in molecular oncology while balancing their clinical or academic responsibilities [2][3] Group 2: Fellowship Benefits - Fellows will receive direct mentorship from Caris experts and faculty at Caris POA institutions, along with access to the CODEai database, which includes data from over 484,000 patients [5] - The program includes collaborative research projects across 97 cancer institutions and structured educational modules, virtual webinars, and lab tours [5] Group 3: Community and Networking - The Fellows Forum will facilitate periodic gatherings for community building and knowledge exchange, including tours of Caris' labs and participation in the Caris POA Summit at the ASCO Annual Meeting [3][4] - Monthly virtual workshops will be held for research updates and skill-building, reinforcing the goal of translating molecular insights into improved patient outcomes [3] Group 4: Company Background - Caris Life Sciences is a leading AI TechBio company focused on precision medicine, utilizing advanced AI and machine learning to analyze complex molecular data [7] - The company aims to transform healthcare through comprehensive molecular profiling and has established a significant clinico-genomic database to support its initiatives [7]

Maze Therapeutics (NasdaqGM:MAZE) 2025 Conference November 20, 2025 07:00 AM ET Company ParticipantsJason Coloma - CEOJason ColomaMorning, everyone. I'm Jason Coloma. I'm the CEO of Maze Therapeutics. First of all, I'd like to thank the Jefferies team for inviting us to this year's conference. I'd also like to acknowledge our forward-looking statements. At Maze, our mission is simple yet ambitious: to harness the power of human genetics to transform the lives of patients. An emphasis for us is chronic kidne ...

Core Insights - Renalytix plc has announced new pivotal data supporting kidneyintelX.dkd as a standard in precision medicine for chronic kidney disease (CKD) [1] - The company’s kidneyintelX.dkd is the only FDA-approved and Medicare-reimbursed prognostic test for early-stage risk assessment in CKD [1] - A manuscript published in Diabetes Care highlights the association of kidneyintelX.dkd with kidney outcomes in the CANVAS and CREDENCE trials [1] Company Overview - Renalytix plc is focused on precision-medicine diagnostics specifically for kidney health [1] - The company has developed kidneyintelX.dkd, which is recognized for its role in early-stage CKD risk assessment [1] Industry Context - The publication of new data in a top-ranked diabetes journal emphasizes the importance of precision medicine in managing chronic kidney disease [1] - The involvement of leading nephrology and metabolism experts from the US, Europe, and Australia in the study underscores the global relevance of the findings [1]

ACADIA Pharmaceuticals (NasdaqGS:ACAD) 2025 Conference November 18, 2025 03:30 AM ET Company ParticipantsCatherine Owen Adams - CEOModeratorGood morning and welcome to the Jefferies 2025 Global Healthcare Conference. It is my pleasure to now introduce Catherine Owen Adams, CEO of Acadia Pharmaceuticals.Catherine Owen AdamsGood morning, ladies and gentlemen. Thank you for joining us here this morning. We are a compact but bijou audience, and I look forward to sharing more about Acadia Pharmaceuticals. Today ...

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation(NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the publication of a landmark study in the high-impact journal Brain. The paper validates that multiplexed Simoa assays for Glial Fibrillary Acidic Protein (GFAP) and Neurofilament Light Chain (NfL) establish a robust, complementary two-pronged approach for comprehensive Multiple Sclerosis (MS) disease activity and pr ...

Accessibility StatementSkip Navigation IRVING, Texas, Nov. 17, 2025 /PRNewswire/ -- Caris Life Sciences®Â (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company will attend the following investor conferences: Contact [email protected] to schedule meetings. About Caris Life SciencesCaris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is acti ...

Company plans to request re-examination after CHMP opinion feedback following its oral explanation FDA advises Company to meet and discuss Company’s Alzheimer's Disease clinical trial results NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, ...

Summary of Bausch + Lomb Investor Day Company Overview - **Company**: Bausch + Lomb (NYSE: BLCO) - **Event**: 2025 Investor Day held on November 13, 2025 Key Industry Insights - **Market Growth**: The eye care market is durable and growing at mid-single digits, with Bausch + Lomb expecting a compound annual growth rate (CAGR) of 5%-7% through 2028 [19][22] - **Consumer Trends**: Increasing consumer interest in self-care, an aging population, and a rise in eye conditions, particularly dry eye, are driving market growth [51] Core Company Strategies - **Financial Excellence**: Emphasis on driving execution, controlling costs, and expanding margins to create sustainable value through 2028 and beyond [16][17] - **Innovation Focus**: A robust pipeline of breakthrough products is expected to deliver significant value beyond 2028, with over 60 active programs in various stages of development [18][34] Financial Targets - **Revenue Growth**: Expected above-market revenue growth with a target of 5%-7% CAGR through 2028 [19][22] - **Margin Expansion**: Targeting an adjusted EBITDA margin of 23% by 2028, reflecting a 600 basis points improvement from 2025 guidance [20][21] - **Cash Flow Generation**: Anticipating cash flow conversion to exceed 50% by 2028, with strong progress already noted in Q3 results [20][28] Product Portfolio Highlights - **Consumer Business**: Strong performance with a 5%-7% CAGR expected, driven by brands like PreserVision, Lumify, and Blink [23][51] - **Pharmaceutical Leadership**: Market leader in dry eye disease with brands Mibo and Xiidra, focusing on innovative treatments [24] - **Surgical Innovations**: Premium IOL portfolio and new product launches are driving growth in the surgical segment [24] Key Product Innovations - **PreserVision AREDS3**: A new formulation targeting all stages of age-related macular degeneration (AMD), expected to launch in 2026 [54][55] - **Lumify Lux**: A new version of the popular redness reliever incorporating hyaluronic acid for enhanced user experience [60][61] - **Blink Triple Care**: An advanced OTC dry eye drop formulation combining hyaluronic acid with nano-emulsion lipids for long-lasting hydration [64] R&D and Innovation - **R&D Transformation**: Significant restructuring to enhance capabilities, focusing on groundbreaking innovations and faster market delivery [33][34] - **Pipeline Potential**: Aiming for peak sales of $7 billion from the current pipeline, with a focus on disruptive innovations rather than incremental improvements [30][31] Market Position and Competitive Advantage - **Leadership in Consumer Eye Health**: Bausch + Lomb is the number one global consumer eye health company, outperforming peers in growth [51][52] - **Brand Trust**: Strong consumer trust in brands like PreserVision, Lumify, and Biotrue, which are highly recommended by eye care professionals [52] Conclusion - Bausch + Lomb is positioned for significant growth through innovative product development, strong financial management, and a commitment to improving eye health standards. The company is confident in its ability to deliver above-market growth and expand profitability through disciplined execution and strategic investments in R&D.

Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially $100 million of total gross proceeds Presented non-human primate data for our potentially first-in-class Activin E antibody, IBIO-610, which may enable only twice-yearly dosing for the treatment of obesity SAN DIEGO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced its fi ...